Table 2.

Demographic and clinical characteristics of RA patients and HCs.

	RA n ​= ​100	HCs n ​= ​100
Age, years	57.6 ​± ​10.3	45.1 ​± ​11.7
Female, n (%)	80 (80)	74 (74)
ESR, mm/h	19.5 ​± ​25	/
CRP, mg/dL	1.34 ​± ​4.8	/
DAS28 score	3.45 ​± ​1.7	/
HAQ score	1.04 ​± ​0.9	/
ACPA positivity, %	65 (65)	/
RF positivity, %	73 (73)	/
Steroid use, %	64	/
Steroid dose, mg/day	1.5 ​± ​2.3	/
DMARDs use, %	86	/
TNFi use, %	27	/
Tocilizumab use, %	13	/
Abatacept use, %	4	/
Rituximab use, %	2	/

RA, rheumatoid arthritis; HCs, healthy controls. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS-28, disease activity score-28 joints; HAQ, health assessment questionnaire; ACPA, anti-citrullinated peptide antibodies; RF, rheumatoid factor; DMARDs, disease-modifying anti-rheumatic drugs; TNFi, tumor necrosis factor-alpha inhibitors.